An important one IMO
We also expanded our portfolio ofdeoxymabs with the addition of PAT-DX3, a humanised full-length IgG deoxymab, late last year.Patrys has completed animal pharmacokinetic (PK) studies for both the PAT-DX1 antibody fragment and thefull-sized PAT-DX3 IgG antibody. Both antibodies have demonstrated pharmaceutically attractive PK profiles,with the differences reflecting in part the different sizes of the antibodies and potential for use in differenttherapeutic applications.
THIS IS HUGE!!!, page-203
-
- There are more pages in this discussion • 194 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
